Biocartis Group NV: Disclosure of a transparency notification


Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today in accordance with Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market (the ‘Belgian Transparency Act’), that it received a transparency notification dated 8 June 2017 (the ‘Notification’), indicating that as a result of the acquisition of voting securities on 1 June 2017, Capfi Delen Asset Management NV now holds 4.94% of the voting rights in Biocartis. As a result, it has crossed the notification threshold of 3%.

The Notification contains the following information:


  • Reason for the Notification: acquisition or disposal of voting securities or voting rights.
  • Notification by: a person that notifies alone.
  • Persons subject to the notification requirement: Capfi Delen Asset Management NV, Jan Van Rijswijcklaan 178, 2020 Antwerp, Belgium.
  • Transaction date: 1 June 2017.
  • Threshold that is crossed: 3%.
  • Denominator: 44,648,105.
  • Details of the Notification: Capfi Delen Asset Management NV holds 2,204,119 voting securities.
  • Chain of controlled undertakings through which the holding is effectively being held: Capfi Delen Asset Management NV is directly controlled by Bank Delen NV, and is ultimately controlled by Stichting Administratiekantoor ‘Het Torentje’. For further information, reference is made to the Notification which is available here on the Biocartis website.
  • Additional information: Capfi Delen Asset Management NV is a management company of UCITS and AIF.


The Notification is available here on the website of the Company.


Pursuant to the Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (‘FSMA’) is required by all natural and legal persons in each case where the percentage of voting rights in the Company held by such persons reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.



Interested in a regular update of the Life Sciences and biotech sector in Flanders?